Expression of myeloid-specific genes in childhood acute lymphoblastic leukemia - A cDNA array study

Leukemia

Volumn 16, Issue 11, 2002, Pages 2213-2221

  Niini, T ^a   Vettenranta, K ^b   Hollmen J ^c   Larramendy, M L ^a   Aalto, Y ^a   Wikman, H ^a   Nagy, B ^a   Seppanen J K ^c   Salvador, A F ^a   Mannila, H ^c   Saarinen Pihkala, U M ^b   Knuutila, S ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c AALTO UNIVERSITY   (Finland)

Author keywords

Acute lymphoblastic leukemia; cDNA array; Gene expression; Myeloid specific genes

Indexed keywords

COMPLEMENTARY DNA;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; B LYMPHOCYTE; BONE MARROW CELL; CELL LINEAGE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOGENETICS; DNA MICROARRAY; FEMALE; GENE EXPRESSION; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; MALE; NERVE CELL; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0036849321     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402685     Document Type: Article

References (57)

1. Ma SK, Wan TS, Chan LC. Cytogenetics and molecular genetics of childhood leukemia. Hematol Oncol 1999; 17: 91-105.
2. Schrappe M, Camitta B, Pui CH, Eden T, Gaynon P, Gustafsson G, Janka-Schaub GE, Kamps W, Masera G, Sallan S, Tsuchida M, Vilmer E. Long-term results of large prospective trials in childhood acute lymphoblastic leukemia. Leukemia 2000; 14: 2193-2194.
3. Gustafsson G, Kreuger A, Clausen N, Garwicz S, Kristinsson J, Lie SO, Moe PJ, Perkkiö M, Yssing M, Saarinen-Pihkala UM. Intensified treatment of acute childhood lymphoblastic leukaemia has improved prognosis, especially in non-high-risk patients: The Nordic experience of 2648 patients diagnosed between 1981 and 1996. Nordic Society of Paediatric Haematology and Oncology (NOPHO). Acta Paediatr 1998; 87: 1151-1161.
4. Hilsenbeck SG, Friedrichs WE, Schiff R, O'Connell P, Hansen RK, Osborne CK, Fuqua SA. Statistical analysis of array expression data as applied to the problem of tamoxifen resistance. J Natl Cancer Inst 1999; 91: 453-459.
5. Swets JA. Measuring the accuracy of diagnostic systems. Science 1988; 240: 1285-1293.
6. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982; 143: 29-36.
7. Good P. Permutation Tests - a Practical Guide to Resampling Methods for Testing Hypothesis, 2nd edn. Springer Verlag: New York, 2000.
8. Yeoh E-J, Ross ME, Shurtleff SA, Williams WK, Patel D, Mahfouz R, Behm FG, Raimondi SC, Relling MV, Patel A, Cheng C, Campana D, Wilkins D, Zhou X, Li J, Liu H, Pui C-H, Evans WE, Naeve C, Wong L, Downing JR. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 2002; 1: 133-143.
9. Hamaguchi H, Yamada M, Noguchi A, Fujii K, Shibasaki M, Mukai R, Yabe T, Kondo I. Genetic analysis of human lymphocyte proteins by two-dimensional gel electrophoresis: 2. Genetic polymorphism of lymphocyte cytosol 64K polypeptide. Hum Genet 1982; 60: 176-180.
10. Zhou LJ, Schwarting R, Smith HM, Tedder TF. A novel cell-surface molecule expressed by human interdigitating reticulum cells, Langerhans cells, and activated lymphocytes is a new member of the Ig superfamily. J Immunol 1992; 149: 735-742.
11. Hibbs ML, Dunn AR. Lyn, a src-like tyrosine kinase. Int J Biochem Cell Biol 1997; 29: 397-400.
12. Su GH, Ip HS, Cobb BS, Lu MM, Chen HM, Simon MC. The Ets protein Spi-B is expressed exclusively in B cells and T cells during development. J Exp Med 1996; 184: 203-214.
13. Yokoyama S, Staunton D, Fisher R, Amiot M, Fortin JJ, Thorley-Lawson DA. Expression of the Blast-1 activation/adhesion molecule and its identification as CD48. J Immunol 1991; 146: 2192-2200.
14. Nagata S, Fukunaga R. Granulocyte colony-stimulating factor and its receptor. Prog Growth Factor Res 1991; 3: 131-141.
15. Bories D, Raynal MC, Solomon DH, Darzynkiewicz Z, Cayre YE. Down-regulation of a serine protease, myeloblastin, causes growth arrest and differentiation of promyelocytic leukemia cells. Cell 1989; 59: 959-968.
16. Rosenberg HF. The eosinophil ribonucleases. Cell Mol Life Sci 1998; 54: 795-803.
17. Weller PF, Bach D, Austen KF. Human eosinophil lysophospholipase: The sole protein component of Charcot-Leyden crystals. J Immunol 1982; 128: 1346-1349.
18. Pui CH, Raimondi SC, Head DR, Schell MJ, Rivera GK, Mirro J Jr, Crist WM, Behm FG. Characterization of childhood acute leukemia with multiple myeloid and lymphoid markers at diagnosis and at relapse. Blood 1991; 78: 1327-1337.
19. Suda T, Suda J, Kajigaya S, Nagata S, Asano S, Saito M, Miura Y. Effects of recombinant murine granulocyte colony-stimulating factor on granulocyte-macrophage and blast colony formation. Exp Hematol 1987; 15: 958-965.
20. de Lau WB, Hurenkamp J, Berendes P, Touw IP, Clevers HC, van Dijk MA. The gene encoding the granulocyte colony-stimulating factor receptor is a target for deregulation in pre-B ALL by the t(1;19)-specific oncoprotein E2A-Pbx1. Oncogene 1998; 17: 503-510.
21. Lutz PG, Moog-Lutz C, Coumau-Gatbois F, Kobari L, Di Gioia Y, Cayre YE. Myeloblastin is a granulocyte colony-stimulating factor-responsive gene conferring factor-independent growth to hematopoietic cells. Proc Natl Acad Sci USA 2000; 97: 1601-1606.
22. Bjurholm A, Kreicbergs A, Brodin E, Schultzberg M. Substance P- and CCRP-immunoreactive nerves in bone. Peptides 1988; 9: 165-171.
23. Guignard F, Mauel J, Markert M. Identification and characterization of a novel human neutrophil protein related to the S100 family. Biochem J 1995; 309: 395-401.
24. Robinson MJ, Hogg N. A comparison of human S100A12 with MRP-14 (S100A9). Biochem Biophys Res Commun 2000; 275: 865-870.
25. Fernandez S, Knopf MA, McGillis JP. Calcitonin-gene related peptide (CGRP) inhibits interleukin-7-induced pre-B cell colony formation. J Leukoc Biol 2000; 67: 669-676.
26. Aalto Y, EI-Rifai W, Vilpo L, Ollila J, Nagy B, Vihinen M, Vilpo J, Knuutila S. Distinct gene expression profiling in chronic lymphocytic leukemia with 11q23 deletion. Leukemia 2001; 15: 1721-1728.
27. Anderson MK, Hernandez-Hoyos G, Diamond RA, Rothenberg EV. Precise developmental regulation of Ets family transcription factors during specification and commitment to the T cell lineage. Development 1999; 126: 3131-3148.
28. Baskaran K, Erfurth F, Taborn G, Copeland NG, Gilbert DJ, Jenkins NA, Iannaccone PM, Domer PH. Cloning and developmental expression of the murine homolog of the acute leukemia protooncogene AF4. Oncogene 1997; 15: 1967-1978.
29. Heim S, Mitelman F. Cancer Cytogenetics, 2nd edn. Wiley-Liss: New York, 1995.
30. Golub TR, Barker GF, Bohlander SK, Hiebert SW, Ward DC, Bray-Ward P, Morgan E, Raimondi SC, Rowley JD, Gilliland DG. Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia. Proc Natl Acad Sci USA 1995; 92: 4917-4921.
31. Romana SP, Mauchauffé M, Le Coniat M, Chumakov I, Le Paslier D, Berger R, Bernard OA. The t(12;21) of acute lymphoblastic leukemia results in a tel-AML1 gene fusion. Blood 1995; 85: 3662-3670.
32. Larsson LG, Schena M, Carlsson M, Sällströöm J, Nilsson K. Expression of the c-myc protein is down-regulated at the terminal stages during in vitro differentiation of B-type chronic lymphocytic leukemia cells. Blood 1991; 77: 1025-1032.
33. Erikson J, Finger L, Sun L, ar-Rushdi A, Nishikura K, Minowada J, Finan J, Emanuel BS, Nowell PC, Croce CM. Deregulation of c-myc by translocation of the alpha-locus of the T-cell receptor in T-cell leukemias. Science 1986; 232: 884-886.
34. Alitalo K, Saksela K, Winqvist R, Alitalo R, Keski-Oja J, Laiho M, Ilvonen M, Knuutila S, de la Chapelle A. Acute myelogenous leukaemia with c-myc amplification and double minute chromosomes. Lancet 1985; 2: 1035-1039.
35. Preisler HD, Kinniburgh AJ, Wei-Dong G, Khan S. Expression of the protooncogenes c-myc, c-fos, and c-fms in acute myelocytic leukemia at diagnosis and in remission. Cancer Res 1987; 47: 874-880.
36. Baer MR, Augustinos P, Kinniburgh AJ. Defective c-myc and c-myb RNA turnover in acute myeloid leukemia cells. Blood 1992; 79: 1319-1326.
37. Romana SP, Poirel H, Leconiat M, Flexor MA, Mauchauffe M, Jonveaux P, Macintyre EA, Berger R, Bernard OA. High frequency of t(12;21) in childhood B-lineage acute lymphoblastic leukemia. Blood 1995; 86: 4263-4269.
38. Shurtleff SA, Buijs A, Behm FG, Rubnitz JE, Raimondi SC, Hancock ML, Chan GC, Pui CH, Grosveld G, Downing JR. TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis. Leukemia 1995; 9: 1985-1989.
39. Borkhardt A, Cazzaniga G, Viehmann S, Valsecchi MG, Ludwig WD, Burci L, Mangioni S, Schrappe M, Riehm H, Lampert F, Basso G, Masera G, Harbott J, Biondi A. Incidence and clinical relevance of TEL/AML1 fusion genes in children with acute lymphoblastic leukemia enrolled in the German and Italian multicenter therapy trials. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Munster Study Group. Blood 1997; 90: 571-577.
40. Niini T, Kanerva J, Vettenranta K, Saarinen-Pihkala UM, Knuutila S. AML1 gene amplification: a novel finding in childhood acute lymphoblastic leukemia. Haematologica 2000; 85: 362-366.
41. Larramendy ML, Huhta T, Vettenranta K, El-Rifai W, Lundin J, Pakkala S, Saarinen-Pihkala UM, Knuutila S. Comparative genomic hybridization in childhood acute lymphoblastic leukemia. Leukemia 1998; 12: 1638-1644.
42. Strom DK, Nip J, Westendorf JJ, Linggi B, Lutterbach B, Downing JR, Lenny N, Hiebert SW. Expression of the AML-1 oncogene shortens the G(1) phase of the cell cycle. J Biol Chem 2000; 275: 3438-3445.
43. Kurokawa M, Tanaka T, Tanaka K, Ogawa S, Mitani K, Yazaki Y, Hirai H. Overexpression of the AML1 proto-oncoprotein in NIH3T3 cells leads to neoplastic transformation depending on the DNA-binding and transactivational potencies. Oncogene 1996; 12: 883-892.
44. Miyoshi H, Ohira M, Shimizu K, Mitani K, Hirai H, Imai T, Yokoyama K, Soeda E, Ohki M. Alternative splicing and genomic structure of the AML1 gene involved in acute myeloid leukemia. Nucleic Acids Res 1995; 23: 2762-2769.
45. Levanon D, Glusman G, Bangsow T, Ben-Asher E, Male DA, Avidan N, Bangsow C, Hattori M, Taylor TD, Taudien S, Blechschmidt K, Shimizu N, Rosenthal A, Sakaki Y, Lancet D, Groner Y. Architecture and anatomy of the genomic locus encoding the human leukemia-associated transcription factor RUNX1/AML1. Gene 2001; 262: 23-33.
46. Rudd CE. Lymphocyte signaling: adapting new adaptors. Curr Biol 1998; 8: R805-R808.
47. Jackman JK, Motto DG, Sun Q, Tanemoto M, Turck CW, Peltz GA, Koretzky GA, Findell PR. Molecular cloning of SLP-76, a 76-kDa tyrosine phosphoprotein associated with Grb2 in T cells. J Biol Chem 1995; 270: 7029-7032.
48. Mizuno K, Katagiri T, Hasegawa K, Ogimoto M, Yakura H. Hematopoietic cell phosphatase, SHP-1, is constitutively associated with the SH2 domain-containing leukocyte protein, SLP-76, in B cells. J Exp Med 1996; 184:1457-463.
49. Nakayama Y, Iwamoto Y, Maher SE, Tanaka Y, Bothwell AL. Altered gene expression upon BCR cross-linking in Burkitt's lymphoma B cell line. Biochem Biophys Res Commun 2000; 277: 124-127.
50. Ornitz DM, Xu J, Colvin JS, McEwen DG, MacArthur CA, Coulier F, Gao G, Goldfarb M. Receptor specificity of the fibroblast growth factor family. J Biol Chem 1996; 271: 15292-15297.
51. Allouche M, Bayard F, Clamens S, Fillola G, Sié P, Amalric F. Expression of basic fibroblast growth factor (bFGF) and FGF-receptors in human leukemic cells. Leukemia 1995; 9: 77-86.
52. Bikfalvi A, Han ZC, Fuhrmann G. Interaction of fibroblast growth factor (FGF) with megakaryocytopoiesis and demonstration of FGF receptor expression in megakaryocytes and megakaryocytic-like cells. Blood 1992; 80: 1905-1913.
53. Pizette S, Coulier F, Birnbaum D, DeLapeyrière O. FGF6 modulates the expression of fibroblast growth factor receptors and myogenic genes in muscle cells. Exp Cell Res 1996; 224: 143-151.
54. Popovici C, Adélaïde J, Ollendorff V, Chaffanet M, Guasch G, Jacrot M, Leroux D, Birnbaum D, Pébusque ML Fibroblast growth factor receptor 1 is fused to FIM in stem-cell myeloproliferative disorder with t(8;13). Proc Natl Acad Sci USA 1998; 95: 5712-5717.
55. Popovici C, Zhang B, Grégoire MJ, Jonveaux P, Lafage-Pochitaloff M, Birnbaum D, Pébusque ML The t(6;8)(q27;p11) translocation in a stem cell myeloproliferative disorder fuses a novel gene, FOP, to fibroblast growth factor receptor 1. Blood 1999; 93: 1381-1389.
56. Guasch G, Mack GJ, Popovici C, Dastugue N, Birnbaum D, Rattner JB, Pébusque MJ. FGFR1 is fused to the centrosome-associated protein CEP110 in the 8p12 stem cell myeloproliferative disorder with t(8;9)(p12;q33). Blood 2000; 95: 1788-1796.
57. Larramendy ML, Niini T, Elonen E, Nagy B, Ollila J, Vihinen M, Knuutila S. Overexpression of translocation-associated fusion genes of FGFR1, MYC, NPMI and DEK, but absence of translocations in acute myeloid leukemia. A microarray analysis. Haematologica 2002; 87: 569-577.